Friday, 6 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Legal & Regulatory

Bliss GVS Pharma Legal & Regulatory

Bliss GVS Pharma was fined Rs. 1,80,000 (excluding GST) by BSE and NSE for failing to appoint a woman director. The fine has been paid to the regulators.

Key figures
Value₹0.02 Cr
Order fromBSE Limited and National Stock Exchange of India Limited
Source

BSE filing, NSE: BLISSGVS. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Bliss GVS Pharma Ltd: key numbers

Share price
₹615.00
Market cap
₹6,543 Cr
Revenue (annual)
₹927.1 Cr
Net profit (annual)
₹129.1 Cr
P/E (TTM)
40.6×Sector 42.0×
Promoter holding
50.07%+15.06% QoQ
FII holding
5.03%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Bliss GVS Pharma Ltd

All →
17:09 IST BSE
Regulatory Approval

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.

Other legal & regulatory announcements

All →